Wellbutrin SR (bupropion) Disease Interactions

There are 5 disease interactions with Wellbutrin SR (bupropion):

Bupropion is primarily metabolized by the liver. The systemic exposure and half-life of bupropion and its metabolites may be increased in patients with hepatic impairment, and drug accumulation may occur to a greater extent than usual. Therapy with bupropion should be administered cautiously in patients with impaired hepatic function, including mild to moderate hepatic cirrhosis. A reduced dose and/or dosing frequency should be considered. Extreme caution is advised in patients with severe hepatic cirrhosis. A dosage reduction is required in these patients, and the dosage should not exceed 75 mg once a day. All patients with hepatic impairment should be closely monitored for possible adverse effects that could indicate high drug or metabolite levels.

The use of bupropion is contraindicated in patients with a seizure disorder. Bupropion may trigger seizures in a dose-dependent manner up to a frequency of 0.4% at 450 mg/day, the maximum recommended dosage. The incidence of seizures increases dramatically at higher dosages (almost 10-fold at 600 mg/day). Because of the wide variability in individual capacity to metabolize drugs and the disproportionate increase in seizure incidence with dosage escalation, bupropion should not be used in patients with underlying seizure disorders. The use of bupropion is also contraindicated in patients with a current or prior diagnosis of bulimia or anorexia because of a higher reported incidence of seizures in such patients treated with the drug. Therapy with bupropion should be administered extremely cautiously in patients with other predisposing factors for seizures, including underlying neurologic abnormalities such as head trauma, brain damage or CNS tumor; excessive use of or abrupt withdrawal from alcohol; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin; and concomitant use of medications that lower seizure threshold. A more gradual titration may be appropriate.

Bupropion may precipitate or aggravate psychotic symptoms, including delusions, hallucinations, confusion, and paranoia. Depressed patients, usually those with bipolar disorder, may experience a switch from depression to mania or hypomania. Patients with psychotic disorders should be monitored for exacerbation of symptoms during bupropion therapy, and the dosing reduced or discontinued and/or additional medications (e.g., tranquilizers) administered as necessary.

Bupropion metabolites, some of which are pharmacologically active with one-fifth to one-half the potency of the parent drug, are excreted by the kidney. Although pharmacokinetic studies have not been conducted in patients with renal impairment, it is conceivable that bupropion and its metabolites may accumulate in such patients to a greater extent than usual. Therefore, therapy with bupropion should be administered cautiously in the presence of significant renal impairment. A reduced dose and/or dosing frequency should be considered, and patients should be closely monitored for possible adverse effects that could indicate high drug or metabolite levels.

The use of bupropion is associated with weight alterations. Both weight gain and weight loss may occur, although the latter is much more common. The incidence of weight loss greater than 5 pounds is approximately 28%, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss. Weight change should be monitored during therapy if bupropion is used in these patients.

You should also know about...

Wellbutrin SR (bupropion) drug Interactions

There are 661 drug interactions with Wellbutrin SR (bupropion)

Wellbutrin SR (bupropion) food/lifestyle Interactions

There are 2 food/lifestyle interactions with Wellbutrin SR (bupropion)

See also...

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2009 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.